Kratom: a dangerous player in the opioid crisis
| Autor: | Mohammad Omar Kalim, Paul N. Foster, Colin Bolzon, Khadija Tayabali, Janki Patel |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
hepatotoxicity lcsh:Internal medicine Herb-induced liver disease scheduled drugs Elevated liver enzymes 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine DEA Internal Medicine Medicine mitragynine 030212 general & internal medicine Intensive care medicine Herbal supplement lcsh:RC31-1245 Drug enforcement kratom business.industry Public health Jaundice Opioid chemistry Press release Mitragynine opioid crisis medicine.symptom business 030217 neurology & neurosurgery FDA medicine.drug |
| Zdroj: | Journal of Community Hospital Internal Medicine Perspectives, Vol 8, Iss 3, Pp 107-110 (2018) |
| ISSN: | 2000-9666 |
| Popis: | Kratom use as a herbal supplement is on the rise in the United States, with reported medical outcomes and lethal effects suggesting a public health threat. Even though the Drug Enforcement Administration has included kratom on its drugs of concern list and the FDA has published a press release to identify it as an opioid with a potential for abuse, its therapeutic and side effects are still not well defined in the literature. Here, we present a case of a 32-year-old man with a history of kratom use who became acutely ill with a brief prodromal illness, followed by jaundice and elevated liver enzymes showing a cholestatic picture, and his successful treatment. In this case, we emphasize the need for awareness of kratom exposure as a key contributor in the expansion of the opioid crisis, with therapeutic benefits earned at the expense of potentially lethal side effects. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |